Prospective Grant of an Exclusive Patent License: NCGC00413972 and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies, 12968 [2022-04829]
Download as PDF
<![CDATA[
12968
Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices
Dated: March 2, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2022–04788 Filed 3–7–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: NCGC00413972 and Its
Related Analogs Consisting of an
Imidazo-Pyrazine Scaffold Core for the
Treatment or Prevention of Cancers
Expressing the Mannose Receptor
CD206, Including Both Solid Tumors
and Hematological Malignancies
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patent Applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice to Macala Bio, Inc. located in
1000 NW Wall Street, Suite 220, Bend,
OR 97703.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before March 23, 2022 will be
considered.
SUMMARY:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Eric Cheng, Ph.D., Licensing
and Patenting Manager at (240)-276–
5530 or eric.cheng2@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
lotter on DSK11XQN23PROD with NOTICES1
United States Provisional Patent
Application No. 62/950,488, filed 19
December 2019 and entitled ‘‘CD206
Modulators Their Use And Methods For
Preparation’’ [HHS Reference No. E–
105–2019/0–US–01];
PCT Patent Application PCT/US2020/
065238, filed 16 December 2020 and
entitled ‘‘CD206 Modulators Their Use
And Methods For Preparation’’ [HHS
Reference No. E–105–2019–0–PCT–02].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
17:25 Mar 07, 2022
Dated: March 2, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2022–04829 Filed 3–7–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Intellectual Property
VerDate Sep<11>2014
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to:
NCGC00413972 and its related analogs
consisting of an imidazo-pyrazine
scaffold core for the treatment or
prevention of cancers expressing the
mannose receptor CD206, including
both solid tumors and hematological
malignancies.
This technology discloses
immunotherapy drugs, and to
compounds that modulate CD206 as
well as their use and methods for
preparation.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Jkt 256001
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request Generic Clearance
for National Cancer Institute (NCI) NCI
Resources, Software and Data Sharing
Forms (National Cancer Institute)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Diane Kreinbrink, Office of
Management Policy and Compliance,
National Cancer Institute, 9609 Medical
Center Drive, Rockville, Maryland, 208
or call non-toll-free number (240) 276–
7283 or email your request, including
your address to: diane.kreinbrink@
nih.gov. Formal requests for additional
plans and instruments must be
requested in writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on December 20, 2021 (Vol. 86
FR 71901) and allowed 60 days for
public comment. No public comments
were received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Cancer Institute (NCI), National
Institutes of Health (NIH), may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid Office of Management
and Budget (OMB) control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, NIH has
submitted to OMB a request for review
and approval of the information
collection listed below.
Proposed Collection: Generic
Clearance for NCI Resources, Software
and Data Sharing Forms, 0925—NEW,
Expiration Date xx/xx/xxxx, NCI, NIH.
Need and Use of Information
Collection: In preparation for
dissemination and sharing of data sets,
forms requesting or applying for access,
upload, share, and store data will be
needed. The purpose of data sharing
E:\FR\FM\08MRN1.SGM
08MRN1
]]>Agencies
[Federal Register Volume 87, Number 45 (Tuesday, March 8, 2022)]
[Notices]
[Page 12968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04829]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: NCGC00413972
and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core
for the Treatment or Prevention of Cancers Expressing the Mannose
Receptor CD206, Including Both Solid Tumors and Hematological
Malignancies
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patent Applications listed in the
Supplementary Information section of this notice to Macala Bio, Inc.
located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before March 23, 2022 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Eric Cheng, Ph.D., Licensing and Patenting
Manager at (240)-276-5530 or [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 62/950,488, filed
19 December 2019 and entitled ``CD206 Modulators Their Use And Methods
For Preparation'' [HHS Reference No. E-105-2019/0-US-01];
PCT Patent Application PCT/US2020/065238, filed 16 December 2020
and entitled ``CD206 Modulators Their Use And Methods For Preparation''
[HHS Reference No. E-105-2019-0-PCT-02].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: NCGC00413972 and its related
analogs consisting of an imidazo-pyrazine scaffold core for the
treatment or prevention of cancers expressing the mannose receptor
CD206, including both solid tumors and hematological malignancies.
This technology discloses immunotherapy drugs, and to compounds
that modulate CD206 as well as their use and methods for preparation.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: March 2, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2022-04829 Filed 3-7-22; 8:45 am]
BILLING CODE 4140-01-P
